Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players
Lucid Diagnostics Inc. (Nasdaq: LUCD) held its inaugural #CheckYourFoodTube Precancer Testing Event for former NFL players in Cincinnati, Ohio. The initiative aims to raise awareness about the link between chronic heartburn and esophageal cancer, and promote EsoGuard® Esophageal DNA Test for precancer detection. The event included an educational session and on-site testing for at-risk former NFL players.
Solomon Wilcots, former Cincinnati Bengals player, emphasized the importance of early detection and encouraged fellow athletes to take proactive steps. Dr. Lishan Aklog, Lucid's CEO, highlighted the opportunity to prevent esophageal cancer through awareness and testing. Lucid plans to expand these events to other cities nationwide, targeting former NFL players and their fans who have risk factors such as heartburn, age over 50, male gender, white race, obesity, smoking, or family history.
Lucid Diagnostics Inc. (Nasdaq: LUCD) ha tenuto il suo evento inaugurale di test precoci #CheckYourFoodTube per ex giocatori della NFL a Cincinnati, Ohio. L'iniziativa mira a sensibilizzare riguardo al legame tra bruciore di stomaco cronico e cancro esofageo, e a promuovere il test del DNA esofageo EsoGuard® per la rilevazione precoce del cancro. L'evento ha incluso una sessione educativa e test in loco per gli ex giocatori della NFL a rischio.
Solomon Wilcots, ex giocatore dei Cincinnati Bengals, ha sottolineato l'importanza della rilevazione precoce e ha incoraggiato i compagni atleti a prendere iniziative proattive. Il Dr. Lishan Aklog, CEO di Lucid, ha evidenziato l'opportunità di prevenire il cancro esofageo attraverso la sensibilizzazione e i test. Lucid prevede di espandere questi eventi in altre città a livello nazionale, mirando a ex giocatori della NFL e ai loro fan che presentano fattori di rischio come bruciore di stomaco, età superiore ai 50 anni, genere maschile, razza bianca, obesità, fumo o storia familiare.
Lucid Diagnostics Inc. (Nasdaq: LUCD) llevó a cabo su evento inaugural de pruebas precoces #CheckYourFoodTube para exjugadores de la NFL en Cincinnati, Ohio. La iniciativa tiene como objetivo crear conciencia sobre el vínculo entre el ardor de estómago crónico y el cáncer esofágico, y promover la prueba de ADN esofágico EsoGuard® para la detección de cáncer en etapas tempranas. El evento incluyó una sesión educativa y pruebas en el lugar para exjugadores de la NFL en riesgo.
Solomon Wilcots, exjugador de los Cincinnati Bengals, enfatizó la importancia de la detección temprana y alentó a sus compañeros atletas a tomar medidas proactivas. El Dr. Lishan Aklog, CEO de Lucid, destacó la oportunidad de prevenir el cáncer esofágico a través de la concienciación y las pruebas. Lucid planea expandir estos eventos a otras ciudades a nivel nacional, dirigido a exjugadores de la NFL y sus aficionados que presentan factores de riesgo como ardor de estómago, edad mayor de 50 años, género masculino, raza blanca, obesidad, tabaquismo o antecedentes familiares.
루시드 다이아그노스틱스 Inc. (Nasdaq: LUCD)는 오하이오주 신시내티에서 NFL 전 선수들을 위한 첫 번째 #CheckYourFoodTube 조기 암 검진 행사를 개최했습니다. 이 이니셔티브는 만성 속쓰림과 식도암EsoGuard® 식도 DNA 검사를 홍보하는 것을 목표로 하고 있습니다. 이 행사에는 교육 세션과 위험에 처한 NFL 전 선수를 위한 현장 검사가 포함되었습니다.
신시내티 벵골스 전 선수 솔로몬 윌콧스는 조기 발견의 중요성을 강조하며 동료 운동선수들에게 적극적인 대처를 할 것을 권장했습니다. 루시드의 CEO인 리샨 악클로그 박사는 인식 제고와 검사를 통해 식도암을 예방할 수 있는 기회를 강조했습니다. 루시드는 이러한 이벤트를 전국의 다른 도시에서도 확대할 계획이며, 위험 요소(속쓰림, 50세 이상, 남성 성별, 백인, 비만, 흡연 또는 가족력 등)가 있는 NFL 전 선수와 그들의 팬들을 대상으로 하고 있습니다.
Lucid Diagnostics Inc. (Nasdaq: LUCD) a organisé son événement inaugural de tests précoces #CheckYourFoodTube pour les anciens joueurs de la NFL à Cincinnati, dans l'Ohio. L'initiative vise à sensibiliser sur le lien entre le reflux gastro-œsophagien chronique et le cancer de l'œsophage, et à promouvoir le test ADN EsoGuard® pour la détection précoce du cancer. L'événement a inclus une session éducative et des tests sur place pour les anciens joueurs de la NFL à risque.
Solomon Wilcots, ancien joueur des Cincinnati Bengals, a souligné l'importance de la détection précoce et a encouragé ses compatriotes athlètes à prendre des mesures proactives. Le Dr Lishan Aklog, PDG de Lucid, a mis en avant l'opportunité de prévenir le cancer de l'œsophage par la sensibilisation et les tests. Lucid prévoit d'étendre ces événements à d'autres villes à l'échelle nationale, en visant les anciens joueurs de la NFL et leurs fans qui présentent des facteurs de risque tels que le reflux, l'âge de plus de 50 ans, le sexe masculin, la race blanche, l'obésité, le tabagisme ou des antécédents familiaux.
Lucid Diagnostics Inc. (Nasdaq: LUCD) hat seine erste #CheckYourFoodTube-Präkanzertestveranstaltung für ehemalige NFL-Spieler in Cincinnati, Ohio, abgehalten. Die Initiative zielt darauf ab, das Bewusstsein für den Zusammenhang zwischen chronischem Sodbrennen und Speiseröhrenkrebs zu schärfen und den EsoGuard® Speiseröhren-DNA-Test zur Früherkennung von Krebs zu fördern. Die Veranstaltung beinhaltete eine aufklärende Sitzung sowie vor Ort durchgeführte Tests für gefährdete, ehemalige NFL-Spieler.
Solomon Wilcots, ehemaliger Spieler der Cincinnati Bengals, betonte die Bedeutung der frühen Erkennung und ermutigte seine Mitspieler, proaktive Schritte zu unternehmen. Dr. Lishan Aklog, CEO von Lucid, hob die Möglichkeit hervor, Speiseröhrenkrebs durch Aufklärung und Tests zu verhindern. Lucid plant, diese Veranstaltungen auf andere Städte im ganzen Land auszudehnen, die sich an ehemalige NFL-Spieler und ihre Fans richten, die Risikofaktoren wie Sodbrennen, über 50 Jahre alt, männliches Geschlecht, weiße Rasse, Fettleibigkeit, Rauchen oder familiäre Vorgeschichte aufweisen.
- Lucid Diagnostics launched a new initiative to raise awareness and promote its EsoGuard® Esophageal DNA Test
- Collaboration with former NFL players may increase visibility and adoption of the test
- Plans to expand the educational and testing events to other cities nationwide
- None.
Insights
This initiative by Lucid Diagnostics to raise awareness about the link between chronic heartburn and esophageal cancer among former NFL players is an interesting approach, but its immediate impact on the company's financials or stock performance is likely While it may help build brand recognition for EsoGuard, the scale of this event seems small and targeted.
The collaboration with former NFL players could potentially lead to broader awareness and adoption of EsoGuard testing, which might translate to increased revenue in the long term. However, without specific data on the event's reach or any financial projections, it's difficult to quantify the potential impact.
For investors, this news primarily indicates Lucid's efforts in marketing and expanding its target audience. It's a positive sign of proactive business development, but not a significant catalyst for immediate stock movement. The long-term value will depend on how successfully Lucid can scale this initiative and convert awareness into actual test orders.
Initiative aims to increase awareness of the relationship between chronic heartburn and esophageal cancer, and role of EsoGuard esophageal precancer testing
This initiative aims to increase awareness of the relationship between gastroesophageal reflux disease (GERD), also known as chronic heartburn, and highly lethal esophageal cancer, as well as the opportunity to prevent this cancer through esophageal precancer detection using Lucid's EsoGuard® Esophageal DNA Test. The event, hosted by Brian J. deGuzman, M.D., Lucid's Chief Technology and Compliance Officer, featured a comprehensive educational session followed by on-site testing of
"Collaborating with Lucid Diagnostics on this inaugural event is just the beginning of what we hope will be a game-changing initiative for former NFL players across the country," said Solomon Wilcots, former NFL player for the Cincinnati Bengals and Team Leader of Sports-Health Alliance at Russo Partners. "As athletes who've put our bodies on the line throughout our careers, we have a heightened awareness of the importance of protecting our long-term health. EsoGuard offers us a crucial opportunity for early detection of esophageal precancer, which can truly be a lifesaver. I strongly encourage all my peers in the sports community to take proactive steps in safeguarding their health from this deadly, yet preventable cancer. Remember, when it comes to esophageal cancer, early detection is the best—it's time we all 'Check Our Food Tubes!'."
"These educational and precancer testing events targeting former NFL players provide us with a great opportunity to increase awareness of highly lethal but now preventable esophageal cancer," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "Individuals with heartburn and other risk factors (age over 50, male, white race, obesity, smoking or a family history), whether former NFL players or their legions of fans, can now undergo a quick and simple test to determine whether they may have precancer and take appropriate steps to prevent this cancer. We are committed to getting the word out and appreciate Mr. Wilcots and his compatriots using their platform to help us do so."
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-holds-inaugural-checkyourfoodtube-precancer-testing-event-for-former-nfl-players-302263758.html
SOURCE Lucid Diagnostics
FAQ
What is the purpose of Lucid Diagnostics' #CheckYourFoodTube Precancer Testing Event?
Who hosted Lucid Diagnostics' (LUCD) inaugural testing event?
What are the risk factors for esophageal precancer mentioned in the Lucid Diagnostics (LUCD) press release?
How does Lucid Diagnostics (LUCD) plan to expand its #CheckYourFoodTube initiative?
